A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs IRX 2 (Primary) ; IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Omeprazole
Indications Cervical cancer; Squamous cell cancer
Focus Therapeutic Use

03 Sep 2023 Planned primary completion date changed from 8 Nov 2023 to 8 Nov 2024.
03 Sep 2023 Status changed from recruiting to active, no longer recruiting.
19 Aug 2022 Planned End Date changed from 8 Nov 2023 to 8 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com